Filtered By:
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Condition: Bleeding

This page shows you your search results in order of date.

Order by Relevance | Date

Total 23 results found since Jan 2013.

Use of oral anticoagulants among individuals with cancer and atrial fibrillation in the United States, 2010 –2016
ConclusionsNearly 7 out of 10 patients with cancer and NVAF did not receive anticoagulation. Use of DOACs increased from 2010 to 2016, with a corresponding decline in warfarin use. DOACs are used less than warfarin among those at higher risk of stroke.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 6, 2022 Category: Drugs & Pharmacology Authors: Shirin Ardeshirrouhanifard, Huijun An, Ravi K. Goyal, Mukaila A. Raji, Jodi B. Segal, G. Caleb Alexander, Hemalkumar B. Mehta Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Use of oral anticoagulants among individuals with cancer and atrial fibrillation in the united states, 2010 ‐2016
ConclusionsNearly 7 out of 10 patients with cancer and NVAF did not receive anticoagulation. Use of DOACs increased from 2010 to 2016, with a corresponding decline in warfarin use. DOACs are used less than warfarin among those at higher risk of stroke.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 3, 2022 Category: Drugs & Pharmacology Authors: Shirin Ardeshirrouhanifard, Huijun An, Ravi K. Goyal, Mukaila A. Raji, Jodi B. Segal, G. Caleb Alexander, Hemalkumar B. Mehta Tags: RESEARCH ARTICLE Source Type: research

Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m2
ConclusionsThis study demonstrated that apixaban and rivaroxaban in patients with a BMI ≥50 kg/m2 for treatment of NVAF may be safe and effective at preventing thromboembolic events and had no increased risk of bleeding. Although, findings should be interpreted with caution and confirmed with additional studies. This study contributes to the growing body of evidence that direct oral anticoagulants (DOACs) may be effective and safe to use for the treatment of NVAF in patients with BMI ≥50 kg/m2.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - December 13, 2021 Category: Drugs & Pharmacology Authors: Cavan P. O ’Kane, Juan Carlo O. Avalon, Jordan L. Lacoste, Wei Fang, Christopher M. Bianco, Laura Davisson, Kara L. Piechowski Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m2
ConclusionsThis study demonstrated that apixaban and rivaroxaban in patients with a BMI ≥50 kg/m2 for treatment of NVAF may be safe and effective at preventing thromboembolic events and had no increased risk of bleeding. Although, findings should be interpreted with caution and confirmed with additional studies. This study contributes to the growing body of evidence that direct oral anticoagulants (DOACs) may be effective and safe to use for the treatment of NVAF in patients with BMI ≥50 kg/m2.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - November 25, 2021 Category: Drugs & Pharmacology Authors: Cavan P. O ’Kane, Juan Carlo O. Avalon, Jordan L. Lacoste, Wei Fang, Christopher M. Bianco, Laura Davisson, Kara L. Piechowski Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Comparative Effectiveness and Safety of Prasugrel versus Ticagrelor following Percutaneous Coronary Intervention: An Observational Study
ConclusionWhen compared with ticagrelor, prasugrel use following PCI for ACS was associated with a lower risk of death, MI, or stroke, as well as a reduced risk of major bleeding.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 1, 2021 Category: Drugs & Pharmacology Authors: Nicholas Belviso, Herbert D. Aronow, Richard Wyss, Marilyn Barbour, Yichi Zhang, Xuerong Wen, Stephen Kogut Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Comparative effectiveness and safety of high ‐dose rivaroxaban and apixaban for atrial fibrillation: A propensity score‐matched cohort study
ConclusionIn this study, composite effectiveness and safety varied between rivaroxaban and apixaban. High ‐dose apixaban was observed to have a better effectiveness and safety.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 27, 2021 Category: Drugs & Pharmacology Authors: Sylvie Perreault, Alice Dragomir, Robert C ôté, Aurélie Lenglet, Brian White‐Guay, Simon Denus, Mireille E. Schnitzer, Marie‐Pierre Dubé, James M. Brophy, Marc Dorais, Jean‐Claude Tardif Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Comparative Effectiveness and Safety of High ‐Dose Rivaroxaban and Apixaban for Atrial Fibrillation: A Propensity Score‐Matched Cohort Study
ConclusionIn this study, composite effectiveness and safety varied between rivaroxaban and apixaban. High ‐dose apixaban was observed to have better effectiveness and safety in patients with AF.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 5, 2021 Category: Drugs & Pharmacology Authors: Sylvie Perreault, Alice Dragomir, Robert C ôté, Aurélie Lenglet, Brian White‐Guay, Simon de Denus, Mireille E Schnitzer, Marie‐Pierre Dubé, James M Brophy, Marc Dorais, Jean‐Claude Tardif Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Comparative Effectiveness and Safety of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome: A Retrospective Cohort Analysis
ConclusionIn this population ‐based cohort of incident ACS patients, ticagrelor was associated with a reduced rate of recurrent nonfatal CVD events and major and minor bleeding events compared with prasugrel.This article is protected by copyright. All rights reserved.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 21, 2019 Category: Drugs & Pharmacology Authors: Ghadeer K. Dawwas, Erich Dietrich, David Winchester, Almut G. Winterstein, Rich Segal, Haesuk Park Tags: Original Research Article Source Type: research

Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation
ConclusionThis real ‐world study suggests that in the setting of polypharmacy and NVAF, rivaroxaban is an effective and safe alternative to warfarin.This article is protected by copyright. All rights reserved.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - December 31, 2018 Category: Drugs & Pharmacology Authors: Brandon K. Martinez, William L. Baker, Nitesh A. Sood, Thomas J. Bunz, Anna ‐Katharina Meinecke, Daniel Eriksson, Craig I. Coleman Tags: Brief Report Source Type: research